The 17 analysts offering 12-month price forecasts for Global Blood Therapeutics Inc have a median target of 115.00, with a high estimate of 152.00 and a low estimate of 64.00. The median estimate represents a +106.91% increase from the last price of 55.58.
The current consensus among 18 polled investment analysts is to Buy stock in Global Blood Therapeutics Inc. This rating has held steady since October, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.73
Reporting Date Nov 04
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.